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A novel bioanalogue hydroxyapatite (HAp)/chitosan phosphate (CSP) nanocomposite has been synthesized by a solution-based
chemical methodology with varying HAp contents from 10 to 60% (w/w). The interfacial bonding interaction between HAp and
CSPhas been investigated through Fourier transforminfrared absorption spectra (FTIR) and x-ray diﬀraction (XRD). Thesurface
morphology of the composite and the homogeneous dispersion of nanoparticles in the polymer matrix have been investigated
through scanning electron microscopy (SEM) and transmission electron microscopy (TEM), respectively. The mechanical
properties of the composite are found to be improved signiﬁcantly with increase in nanoparticle contents. Cytotoxicity test using
murine L929 ﬁbroblast conﬁrms that the nanocomposite is cytocompatible. Primary murine osteoblast cell culture study proves
thatthenanocompositeisosteocompatibleandhighlyinvitroosteogenic.TheuseofCSPpromotesthehomogeneousdistribution
of particles in the polymer matrix through its pendant phosphate groups along with particle-polymer interfacial interactions. The
prepared HAp/CSP nanocomposite with uniform microstructure may be used in bone tissue engineering applications.
Copyright © 2009 Nabakumar Pramanik et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hydroxyapatite (Ca10(PO4)6(OH)2) (HAp) is an interesting
biomaterial with potential orthopedic, dental, and max-
illofacial applications due to its excellent biocompatibility,
bioactivity, and osteoconductivity [1]. HAp, being chemi-
cally and structurally similar to the inorganic component
of bone, enamel, and dentin has received considerable
attentionfromthebiologistsandbiomaterialscientists.Ithas
been successfully used as bone ﬁllers, aesthetic restorative,
coating of orthopedic implants, ﬁller of inorganic/polymer
composites, cell-culture carriers, and so on. It is, however,
worth-mentioning that the application of pure HAp is being
limited, due to its brittleness. In recent years, the develop-
ment of bioactive ceramic-polymer composites commonly
known as bioanalogue has gained a phenomenal impetus
in the orthopedic ﬁeld for their bone analogue design
as well as good biological and mechanical performances
to meet speciﬁc clinical requirements [2–4]. The idea is
to use a ceramic-polymer composite material that can
develop a considerable anisotropic character by means of
adequate orientation techniques reinforced with a ceramic
that simultaneously assures the mechanical reinforcement
and the bioactive character of the implant [4–7]. In fact,
natural bone tissue is a biocomposite, composed of nano-
hydroxyapatite (n-HAp) crystals dispersed in a collagen
matrix.
In the design of hydroxyapatite-based bioanalogue com-
posites, the most commonly used matrices include poly-
mers like poly(methyl methacrylate) (PMMA), high-density
polyethylene(HDPE),poly-L-lactide(PLA),andmanyother.
However, the natural biopolymers have received much2 International Journal of Biomaterials
attention in the ﬁelds of orthopedic and other biomedical
applications, due to their excellent biocompatibility and
biodegradability [8]. Chitosan (poly-1,4-D-glucosamine), a
partially deacetylated form of chitin, is structurally similar
to glycosaminoglycan, and has many desirable properties as
tissue engineering scaﬀolds [9].
The mechanical properties of an HAp/polymer com-
posite can be signiﬁcantly improved by controlling the
interfacial bonding between matrix and the reinforcement;
and without proper interface control, a brittle, polyphase
material results rather than a toughened composite. Various
methodologies have been developed to improve the interfa-
cialbondingbetweenthesame[10,11].Nevertheless,theuse
of judiciously chosen coupling/anchoring agents has been
proved as a reliable method to strengthen the interfacial
bonding between the ﬁller and polymer matrix with an
appreciable enhancement of the compatibility by making
the chemical bridges between the same. Organosilane- and
organotitanate-based coupling agents have already been
reported to tailor the particle surface properties by lowering
their speciﬁc surface energy [12, 13]. Recently, grafting
of organophosphorus coupling agents (OPCAs) on pre-
formed inorganic supports or in-situ formation of the
inorganic part in presence of organophosphorus reagents
oﬀers a potential alternative to the silicon- or titanate-
based coupling agents. Based on the ability of phospho-
nate ions to exchange with the phosphate ions on HAp
crystals, any polymer containing a number of phosphate
or phosphonic acid groups is expected to have higher
aﬃnity for the HAp particles [14]. Moreover, the phosphate-
containing polymers are expected to have higher mechan-
ical properties and biocompatibility [15]. In the prepa-
ration of bioanalogue composites, organophosphonate- or
phosphate-basedcoupling/anchoringagentsarebeingexten-
sively used by the researchers to improve the compatibility
between inorganic nanoparticles and polymer matrix [16–
20]. Greish and Brown have developed a biocompatible
HAp-Ca poly(vinyl phosphonate) composite for clinical
applications [14]. Varma et al. have reported the preparation
of calcium phosphate-coated phosphorylated chitosan ﬁlm
byabiomimetic method[18].Tanakaetal.havereportedthe
synthesis of surface-modiﬁed calcium hydroxyapatite with
pyrophosphoric acid for use as bioceramics, particularly for
orthopedic applications [19]. Choi et al. have reported the
preparation of surface-modiﬁed hydroxyapatite nanocrystals
by grafting of polymers containing phosphonic acid groups
[20]. Phillips et al. have grafted allyl phosphonic acid on
calcium phosphate to produce a chemically bonded com-
posite with superior mechanical properties [21]. All these
studies unequivocally suggest that phosphonate/phosphoric
acid-based coupling agents can be successfully employed to
enhance the interfacial bonding between the particles and
the polymer matrix, and hence to improve the mechanical
properties of the resulting composites.
In the present paper, we have attempted to prepare
hydroxyapatite (HAp)/chitosan phosphate (CSP) nanocom-
posite through a simple solution-based chemical method,
which has the potential of providing much better dispersion
of n-HAp particles in the polymer matrix yielding a com-
posite with uniform microstructure. CSP has been chosen as
polymer matrix because phosphate groups of CSP can act as
coupling/anchoring agent, which is a good cation absorber
and has higher aﬃnity towards the n-HAp particles [15].
Moreover, it is easy to prepare from cheaper ingredients.
We havealso extensively studied the dispersion, morphology,
nanoparticle-polymermatrixbondinginteractions,mechan-
i c a lp r o p e r t i e s ,a sw e l la si nv i t r ob i o c o m p a t i b i l i t ya n d
osteogenicity of the synthesized HAp/CSP nanocomposite.
2.MaterialsandMethods
2.1. Chemicals. Calcium nitrate (Ca(NO3)2·4H2O) (99%),
diammonium hydrogen phosphate ((NH4)2HPO4) (DAHP)
(99%), ammonia solution (25%), ammonium chloride
(98%), triethanolamine (TEA), and orthophosphoric acid
(H3PO4) were procured from Merck, Mumbai, India. Chi-
tosan, methyl-thiotetrazole (MTT), trypsin, dexamethasone,
sodium beta-glycerol phosphate, and SEM grade gulter-
aldehyde were purchased from Sigma-Aldrich Chemical,
St Louis, Mo, USA. Collagenase type I, 0.25% trypsin-
EDTA, and Dulbecco’s modiﬁed Eagle’s medium (DMEM)
were procured from Invitrogen, USA. Fetal calf serum and
alpha-MEM were supplied by Hyclone and Pan-Biotech,
respectively.
2.2. Preparation of Nano-Hydroxyapatite (n-HAp). Ac o n -
centration of 0.5M stock solution each of Ca(NO3)2·4H2O
and (NH4)2HPO4 was prepared in distilled water. Both
solutions were taken in such amounts that Ca:P molar
ratio was maintained at 1.67. Triethanolamine (TEA)
was used in conjunction with Ca(NO3)2·4H2Os o l u t i o n
(Ca2+ :TEA= 1:0.5) as a capping agent to control the
particle growth during precipitation. The pH of both
calcium nitrate and DAHP solutions was maintained at ∼11-
12. (NH4)2HPO4 was added drop-wise to the mixture of
Ca(NO3)2·4H2O and TEA and vigorously stirred at room
temperature using a mechanical stirrer (2500rpm). The pH
of the reacting mixture was also maintained in the range
of 11-12 by adding NH4OH solution gradually. The process
was continued up to 6 hours. The gelatinous precipitate thus
obtained was ﬁltered by a centrifugal ﬁltration process. The
precipitate was washed with water thoroughly as well as with
NH4ClsolutiontoremovetheexcessresidualTEA,anddried
at 90◦C for 15 hours.
2.3. Synthesis of Chitosan Phosphate (CSP). Am i x t u r eo f
approximately 2g chitosan powder, 100mL of 2% acetic
acid solution, 6g of orthophosphoric acid was taken in a
three naked-round bottomed ﬂask equipped with a stirrer,
condenser, thermometer, and nitrogen gas inlet tube. The
mixture was heated up to 80◦C under constant stirring
until dissolution of chitosan powder and then heated to
reﬂux. After 2 hours, the resultant solution was cooled and
precipitated in excess methanol. Again, the precipitated gel
was dissolved in water and all unreacted phosphate (H3PO4)
and acetic acid were removed by repeated reprecipitationInternational Journal of Biomaterials 3
in excess methanol. Finally, the gel was collected and dried
under vacuum oven at 80◦C over night.
2.4. Synthesis of HAp/CSP Nanocomposite. At ﬁrst, the CSP
was dissolved in hot water, and then the nanoparticles
were added slowly with vigorous stirring with the help of
a mechanical stirrer at 3000rpm. After addition of entire
nanoparticles to the polymer solution, the resulting solution
mixture was kept in a vacuum desiccator to remove the
bubbles. Then, the mixture was heated in a water bath to
evaporate water. The resulting slurry was poured into a
glass petri dish and dried to make a ﬁlm, keeping it in a
vacuum oven at 90◦C over night. After that, the ﬁlm was
cut into dumbbell-shaped samples. Six sets of HAp/CSP
nanocomposites were prepared by adding 10 to 60wt.% of
n-HAp particles as ﬁller.
2.5. Characterization
2.5.1. Physicochemical Characterization
(1) XRD Study. The phase analysis of the HAp powder
and composite samples was done by XRD (Model PW
1729, Philips, Holland) using 35 milliamps, and 40kV
current, with a monochromatic CuKα (target) radiation (λ =
1.5405 ˚ A) with a step size of 0.04◦2θ, a scan rate of 0.02◦2θ/s,
and a scan range from 2θ = 10 to 60◦.
(2) FTIR Study. The identiﬁcation of functional groups in
the HAp powder, matrix, and composite samples as well as
the interfacial modiﬁcation (i.e., nature of bonding between
particles and the polymeric matrix) were analyzed by FTIR
analysis (Model NEXUS870, FTIR, Thermo Nicolet, USA)
within the scanning range 4000–400cm−1.
(3) TEM Study. The morphology, particle size of HAp
powder, and dispersion of particles in the polymer matrix
were observed through a Phillips CM 200 transmission
electron microscope (TEM) with an acceleration voltage
200kV.
(4)SEMStudy. Thesurfaceroughnessofthenanocomposite
samples was investigated by scanning electron microscopy
(SEM) (Model JSM-5800, JEOL, scanning electron micro-
scope, Japan).
(5) Mechanical Testing. The tensile testing of the composite
ﬁlms was carried out on a universal mechanical testing
machine (Model H10KS, HOUNSFIELD, UK) at a crosshead
rate of 50mm/min.
2.5.2. Biocompatibility Study
(1) Cell Viability Study. In vitro cytotoxicity study of the
material was carried out by culturing murine ﬁbroblast L929
cells in a contact mode. Brieﬂy, L929 cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and seeded
on the sheets/ﬁlms at their exponential phase of growth at
ad e n s i t yo f1 0 5 cells/cm2. The cells were allowed to attach
to the ﬁlms surface for 3 hours in 5% CO2 incubator at
37◦C. Fresh DMEM medium supplemented with 10% fetal
calf serum (FCS) was added to each well to keep the cell
containing ﬁlms submerged. The plates were incubated for
2 4h o u r sa t3 7 ◦C in a humidiﬁed atmosphere of 5% CO2 in
air. After 24-hour incubation, MTT (4mg/mL) was added to
eachwellatastrengthof10%(v/v)andincubatedforfurther
4 hours at 37◦C. Subsequently, the media containing MTT
wasremoved,and200μLofDMSOwasaddedtodissolvethe
formazan crystals. The absorbance was measured using an
ELISA plate reader (Biorad, USA) at 595nm. Student paired
t-test was performed to test for statistical signiﬁcance, and
a P-value of <.05 was determined to represent a signiﬁcant
diﬀerence.
(2) Primary Murine Osteoblast Culture. Primary murine
osteoblastcellswereobtainedbyserialenzymaticdigestionof
neonatalmicecalvariae.Brieﬂy,calvariaeweredissectedfrom
3-4 days old neonatal mice. After removing adherent mes-
enchymal tissue and periosteum, calvariae were subjected to
ﬁve sequential 15-minute digestions in an enzyme mixture
containing 0.05% trypsin and 0.1% collagenase type I at
37◦C on a rocking platform. The ﬁrst two fractions were
discarded, and fractions 3–5 were collected and immediately
chilled by the addition of cold DMEM containing 10%
FCS. Released cells were pooled, centrifuged, resuspended
in medium, and ﬁltered through a 70-micron mesh. Cells
were plated at 104 viable cells/cm2 in six-well culture plates
in DMEM containing 20% FCS. Then, 24 hours later,
the medium was changed to Dulbecco’s modiﬁed Eagle’s
medium with 10% FCS (basal medium), and cells were fed
again after 3 days. The cells from third to ﬁfth passages were
used for the diﬀerentiation studies.
(3) In Vitro Osteoblast Diﬀerentiation. Conﬂuent monolay-
ers of osteoblastic cells were enzymatically lifted from the
ﬂasks using 0.25% trypsin in 4mM EDTA. The cells were
concentrated by centrifugation at 300g for 10 minutes and
resuspended in a known amount of media [22]. Cells were
counted using hemocytometer and diluted to the desired
concentration of cells in complete media containing alpha-
MEM supplement with 10% FBS, 1% antibiotic-antimycotic
solution, 10μM sodium beta-glycerol phosphate, 50μg/mL
L-ascorbic acid, and 100nM dexamethasone. Aliquots of
20μL of cell suspension were seeded onto the top of the ﬁlms
prewetted and equilibrated with complete media placed in
the wells of 24-well plates resulting in a seeding density of
104 cells/cm2.Theﬁlmswereleftundisturbedinanincubator
for 3 hours at 37◦C to allow for cell attachment to the ﬁlms,
after which an additional 1mL of complete media was added
to each well. Medium was changed every 3 days. Cultures
were maintained in a humidiﬁed atmosphere consisting of
5% CO2 at 37◦C. Osteoblast proliferation was determined at
3,7,14and21days.Theﬁlmsweregentlywashedusingfresh
medium to remove unattached cells and exhausted medium
followed by MTT assay as described above.4 International Journal of Biomaterials
(4) Alkaline Phosphatase Assay. Culture medium was re-
moved from the ﬁlms and the cells were washed twice with
PBS. The cells were lysed with 250μL of Triton X-100 (0.01%
in PBS) for 30 minutes at 4◦C. The obtained homogenate
was used for the measurement of alkaline phosphatase
(AP) activity and total protein concentration. AP activity
was determined by an assay based on the hydrolysis of p-
nitrophenyl phosphate to p-nitrophenol. About 50μL of the
Tritonlysatewasaddedto125μLofactivereagentcontaining
0.012M p-nitrophenyl phosphate in 0.05M diethanolamine,
pH 9.8, and incubated for 30 minutes at 37◦C. The reaction
was stopped with 50μLo f2 . 5Ms o d i u mh y d r o x i d ea n dt h e
AP activity was determined by measuring the absorbance of
p-nitrophenol at 405nm using a Microplate Reader (Bio-
Rad).
(5) Osteoblasts Morphology and Their Nodule Formation.
Osteoblasts morphology and their nodule formation were
investigated through scanning electron microscope (SEM)
study. For SEM studies, the attached cells on the composite
ﬁlms were rinsed twice with PBS, and ﬁxed with 250mL
of 2.5% glutaraldehyde in PBS for 30–60 minutes. After
washing with PBS, dehydration was performed by slow water
replacement using series of ethanol solutions (30%, 50%,
70%, and 90%) for 15 minutes with ﬁnal dehydration in
absolute ethanol for 30 minutes, allowing samples to dry
at room temperature and under vacuum. The ﬁlms were
mounted on stubs and coated in vacuum with gold. Cells
were examined with a JSM-5800, JEOL, scanning electron
microscope, Japan.
3. Results andDiscussion
3.1. Physicochemical Study
3.1.1. XRD Study. Figure 1(b) shows the X-ray diﬀrac-
tion pattern of the synthesized apatite powder. The
d-values correspond to that of calcium hydroxyapatite
(Ca10(PO4)6(OH)2) (JCPDS card no. 74-0566). Taking into
account the broadening of each peak in XRD, mean crys-
tallite size has been calculated using Scherrer’s equation,
that is, D = 0.9λ/βcosθ,w h e r eD is the average crystallite
size in ˚ A, β is the peak broadening of the diﬀraction line
measured at half of its maximum intensity in “radian,” λ
is the wavelength of X-rays, and θ is the Bragg’s diﬀraction
angle. The mean crystallite size is found to be 15nm. The
approximate particle size of HAp powder is found to be 6–
10nm in diameter by 26–56nm in length with needle-like
acicularcrystalsashasbeenobservedfromTEMmicrograph.
The use of synthesized n-HAp powder with the CSP polymer
as a matrix thus provides an eﬀective means to produce
nanocomposites.
Figure 1(c) shows the X-ray diﬀraction pattern of the
HAp/CSP composite. The crystallite size of HAp in com-
posite is found to be 12nm. The crystallinity (Xc) of the
pure HAp and HAp/CSP composite is determined by an
empirical relation between Xc and β002 (i.e., β002 ×
3 √
Xc =
KA)[ 23], where Xc is the crystallinity degree, β002 is full
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Figure 1: X-ray diﬀraction patters of (a) CSP, (b) HAp, and (c)
HAp/CSP nanocomposite.
width of the peak at half intensity of (002) plane in degree
−2θ,a n dKA is a constant (0.24). The Xc for pure HAp
powder is 0.15, and in the HAp/CSP composite, it is found
to be 0.11. The crystallinity of the n-HAp particles as well
as CSP polymer has decreased after composite formation
as shown in Figure 1 indicating that crystal structures of
both HAp and CSP have changed after composite formation,
which may be resulted from the interface binding between
particles and matrix. The XRD peaks, (002) and (211) have
shifted to higher 2θ values in case of HAp/CSP composite
as compared to pure HAp (i.e., from 2θ = 25.98 to
26.57 and 31.89 to 33.46, resp.), which is possibly due to
compressionfromthecontractingpolymeric matrixthrough
interfacial bonding. Simultaneously, the crystalline peak of
CSP polymer at 2θ = 20.8 has shifted to 21.6, whereas,
another crystalline peak of CSP at around 2θ = 10.5h a s
disappeared in the composite (Figure 1(c)). The shift and
decreaseincrystallinityofeachpeakofthepolymeraswellas
HAp after composite formation clearly indicate the presence
of bonding between HAp particles and polymer matrix. The
peak at 32.49 [300]of n-HAp is weakened after composite
formation, which also indicates the participation of n-HAp
in bonding with the polymer.
3.1.2. FTIR Study. Figure 2(b) shows the FTIR spectrum
of CSP having characteristic peaks at 2934 and 2850cm−1
for asymmetric and symmetric stretching of methylene
(–CH2–) groups, respectively. On the other hand, the bands
at around 1544 and 1620cm−1 are for N–H stretching
in CSP. The bands at around 1088 and 1047cm−1 are
attributed to the C–O–P stretching and phosphorylated
hydroxyl group, whereas, the characteristic peaks at around
991 and 493cm−1 are attributed for P–OH groups in CSP
polymer. The bands at around 1100 to 1250cm−1 are dueInternational Journal of Biomaterials 5
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Figure 2: FTIR spectra of (a) chitosan, (b) chitosan phosphate, (c)
HAp powder, and (d) HAp/CSP nanocomposite.
to P–O, P=O stretching of phosphate group. The bands at
632 and 3571cm−1 are for structural OH groups in the n-
HAp crystals (Figure 2(c)). The bands at 1092, 1030, and
604cm−1 indicate the presence of PO4
3− group, and the
spectrum also indicates the presence of H2O (3422 and
1641cm−1) in HAp crystals. The peaks at 1047 and 493cm−1
for P–OH groups in CSP have disappeared as shown in
the Figure 2(d) for HAp/CSP composite, which may be due
to the formation of polyphosphonate salt [14]. The peak
intensity of P–OH at 991 and 1088cm−1 in CSP polymer has
decreased after composite formation, which evidences that
theP–OHgroupsofCSPpolymerhavetakenpartinbonding
withhydroxyapatite.SimilartrendisseenincaseofOH(632,
3571cm−1) groups of HAp crystals, which is an indication of
participation in bonding of HAp with polymer. Most of the
peaks either in polymer or in HAp have shown clear shift
after composite formation (Table 1). Thus, a comparison
of the FTIR analysis has indicated that there is a chemical
bonding at the nanoparticle-polymer interface.
3.1.3. TEM Study. Figure 3(a) shows the TEM micrograph
of the synthesized n-HAp powder. The micrograph depicts
theacicularneedle-likecrystalsofHAppowderinnanometer
range, having 6–10nm in diameter by 26–56nm in length.
The micrograph shows the presence of agglomerations
among the particles, which are due to high speciﬁc surface
energy of n-HAp particles resulting in their aggregations.
Nanosized HAp particles with homogeneous dispersion are
well identiﬁed in case of HAp/CSP composite (Figure 3(b)).
The particle size of HAp is also controlled by the polymer
(CSP) in composite as depicted in the TEM micrograph.
3.1.4. SEM Study. Figure 4 shows the SEM micrographs of
fracture surface of the composite samples with diﬀerent
50nm
(a)
100nm
(b)
Figure 3: TEM micrographs of (a) HAp powders and (b) HAp/CSP
nanocomposite (40% w/w).
5μm
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5μm
(b)
5μm
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5μm
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Figure 4: SEM micrographs of HAp/CSP nanocomposite samples
with various contents of n-HAp particles (a) 20% (w/w), (b) 30%
(w/w), (c) 40% (w/w), and (d) 50% (w/w).
contents of n-HAp particles. The micrographs depict that
withincreaseinamountofHApparticlesloading,thesurface
roughness for the composites is increased.
3.1.5. Mechanical Properties Study. The tensile strength and
modulus of the composites are found to be increased with
increase in amount of HAp contents (Table 2). In 30%
(w/w) n-HAp content, the increase in tensile strength and
modulus has been found to be 100.4% and 190.8% than
pure CSP polymer, respectively. In 40% (w/w) HAp loading,
the tensile strength and modulus are increased by 140.8%
and 225.5%, respectively. With 50% (w/w) HAp content,
the tensile strength started to decrease, whereas, modulus
is increased by 381.5% over pure CSP polymer. The results
are summarized in Table 2. From the results, it is clear that
the mechanical properties have been improved signiﬁcantly
with high nanoparticle loading capability, which means that
the composite tends to be used as a biomaterial with high
osteoconductivity [24]. The enhancement in tensile strength
and modulus in case of HAp/CSP nanocomposite could6 International Journal of Biomaterials
Table 1: FTIR peak positions of various functional groups before and after composite formation.
Functional groups
IR peak positions (cm−1)
CS CSP HAp particles HAp/CSP
PO4
3− — — 1092, 1030, 604 1079, 1025, 602
P–OH — 1088, 1047, 991, 493 — 1070, disappeared, 984, disappeared
O–H bending — — 632, 3571 625, 3563
O–H stretching 3430 3427 3422 3402
N–H 3467, 1622, 1544 3465, 1620, 1544 — 3462, 1620, 1543
CS CSP HAp/CSP
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Figure 5:CellviabilitytestusingmurineﬁbroblastcelllineL929on
CSP and HAp/CSP ﬁlms, CS was taken as control (n = 3).
be attributed to the excellent bonding at the nanoparticle-
polymer matrix interface through the pendant phosphate
groups of CSP.
3.2. Biocompatibility Study
3.2.1. Cell Viability Study. A cell line of murine ﬁbroblast
(L929) has been selected for the MTT assay test. The
diﬀerence in cell viability index is shown in Figure 5 of the
composite samples of diﬀerent concentrations, as compared
to the control tissue culture plate. The statistical analysis
(Student’s t-test) has indicated that the diﬀerence in cell via-
bility index is insigniﬁcant. Hence, the developed composite
is cytocompatible.
3.2.2. In Vitro Osteoblast Diﬀerentiation Study. The neonatal
mouse calvarial osteoblasts have been used to study the
development of bone cells on CSP and HAp/CSP nanocom-
posite ﬁlm surfaces. The results of cell proliferation of
murine calvarial osteoblasts cultured on CSP and HAp/CSP
nanocomposite ﬁlms show a cell proliferation during the
ﬁrst 7 days (Figure 6). The proliferation phase follows a
growth retardation after 7 days due to high conﬂuence of
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Figure 6: Osteoblast cell proliferation on CSP and HAp/CSP ﬁlms,
CS was taken as control. Signiﬁcant increase in cell number (P<
.001)wasfoundatday7inallthevariationsfollowedbyretardation
of growth phase.
cells on the ﬁlm surfaces. The results show that HAp/CSP
nanocomposite is an appropriate biomaterial for osteoblast
proliferation.
3.2.3. Alkaline Phosphatase Enzyme Activity Study. The dif-
ferentiation process of the osteoblast cells on CSP and
HAp/CSP nanocomposite has been analyzed by the alka-
line phosphatase (AP) enzyme activity, which is an early
osteogenic marker. The highest enzyme activity is achieved
at day 14 in both materials (Figure 7). The AP activity shown
by osteoblast cells growth on HAp/CSP nanocomposite is
signiﬁcantly higher than that on CSP surface.
3.2.4. Osteoblasts Morphology and Their Nodule Formation.
Further, SEM examination has been conducted at day 14
to observe the bone formation process. Osteoblast cultured
on the chitosan ﬁlms reveals a round shape and stayed
segregated. Secreted extracellular matrix or mineralization
is not observed there (Figure 8(a)). Whereas, osteoblast
cultured on chitosan phosphate ﬁlms has shown tight aggre-
gation and some mineralization (Figure 8(b)). However,
osteoblast cultured on HAp/CSP nanocomposite shows a
characteristic growing in multiple-layer patterns and tendsInternational Journal of Biomaterials 7
Table 2: Mechanical properties of HAp/CSP nanocomposite samples. Number after ± sign corresponds to the standard deviation.
n-HAp particles loaded (w/w) Tensile strength (MPa) Young’s modulus (MPa) Elongation at break (%)
0% 6.37 ± 0.55 74.45 ±0.94 72.87 ±2.66
10% 7.57 ± 0.29 147.87 ±1.23 47.99 ±2.17
20% 10.43 ±0.87 184.89 ±2.77 33.95 ±0.66
30% 12.77 ±1.06 216.56 ±3.45 30.84 ±1.84
40% 15.34 ±0.47 242.38 ±2.76 22.28 ±2.58
50% 11.89 ±0.78 358.54 ±4.85 20.77 ±1.42
60% 10.65 ±0.49 302.68 ±3.97 18.76 ±0.95
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Figure 7: AP activity of osteoblast cells grown on CSP and
HAp/CSP ﬁlms, CS was taken as control. Both in case of CSP
and HAp/CSP enzyme activity increased up to day 14 (P<. 001).
HAp/CSP nanocomposite is proven a better support for osteoblast
diﬀerentiation than CSP alone (P<. 01).
to form a nodular cell aggregation (Figure 8(c)). Nodules
contain densely packed cells are embedded within highly
mineralized extracellular matrix secreted by them. SEM and
AP enzyme activity studies indicate that incorporation of
hydroxyapatite increases in vitro osteogenicity of chitosan
phosphate ﬁlms.
4. Summary and Conclusions
AnovelbioanalogueHAp/CSPnanocompositewithuniform
dispersion of n-HAp particles has been synthesized success-
fully following a solution-based chemical methodology with
an appreciable improvement in mechanical properties and
minimal surface defects. XRD and FTIR analyses clearly
conﬁrm the presence of interfacial bonding interaction
between the ﬁller and matrix. The use of CSP acts as a cou-
pling/anchoring agent and provides a signiﬁcant platform
for better dispersion of nanoparticles in the polymer matrix
through its pendant phosphate groups. Cytotoxicity test
conﬁrms that the developed composite is cytocompatible.
(a) (b)
1
2
3
(c)
Figure 8: SEM images of osteoblasts grown on diﬀerent matrices
at day 14 on (a) chitosan (CS), (b) chitosan phosphate (CSP), (c)
HAp/CSP nanocomposite. Scale bar of each image is 10μm. Arrow
“1”showsanodularcellaggregate,arrow“2”showstheextracellular
matrix secreted by the cells in around themselves, and arrow “3”
shows a visible mineral nodule.
Primary murine osteoblast cell culture study proves that
the HAp/CSP nanocomposite is osteocompatible and highly
osteogenic in vitro. The uniform dispersion of HAp particles
using CSP through its pendant phosphate groups followed
byimprovementinmechanicalpropertiesofthecompositeis
an important parameter in order to improve the bioactivity.
Therefore, the developed HAp/CSP nanocomposite may be
potentially used in bone tissue engineering applications.
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